W
WAVEMAN · COMPANY
ADCT · Adc Therapeutics Sa
> Ask across nine datasets ⌘K
LIVE
TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475TEAM-0.32% 13F +439META+2.47% 13F +2,694RCG-2.04% CLUSTERUTHR-4.03% 13F +425CRWV-1.12% 13F +693CRM-0.46% 13F +1,018CVNA+2.74% 13F +794TPL-0.71% 13F +444NET-4.47% 13F +710MSTR-1.35% 13F +526DELL+15.81% 13F +1,203CRWD-5.42% 13F +1,382ANET+2.87% 13F +1,323COIN-1.05% 13F +475
← ALL COMPANIES

ADCT

ADC Therapeutics SA
PHARMA & BIOTECH · PHARMACEUTICAL PREPARATIONS · CIK 0001771910
SEC FILINGS☆ WATCH
INSIDER NET · 180D
-$19.6M
open-market buys minus sells, Form 4 codes P and S
INSIDER BUYERS · 180D
0
CONGRESS BUYERS · 1Y
0
FUNDS ADDED · QTR
70
13F, latest reported quarter
REVENUE GROWTH
+14.9%
XBRL, annual
NET MARGIN
-175.3%
SEVEN FACTS, RANKED AGAINST THE SECTOR · RANK IS NOT A FORECAST
INSIDERS
net -$19.6M over 180 days
-$19.6M of it by a 10%+ holder
below 88% of Pharma & Biotech
CONGRESS
no member of Congress has reported trading it
FUNDS
70 funds added or opened last quarter
more than 54% of Pharma & Biotech
REVENUE
+14.9% year over year
more than 64% of Pharma & Biotech
MARGIN
-175.3% net margin
below 71% of Pharma & Biotech
BUYBACKS
no share repurchases reported
SHORT
4.0% of shares outstanding short · 6.1 days to cover · settled 2026-07-31
below 52% of Pharma & Biotech
THE SITUATION · EVERY LINE IS ONE RULE OVER ONE DATASET
70 funds added or opened positions in the latest 13F quarter, of 116 holders.
The year, with the filings on it
Total return indexed to 100 over the last 12 months · every marker is a federal filing, placed at its date — hover any marker for the detail
TOTAL 12M RETURN -57.4%
-57.4%12M
-69%-27%+15%+57%2025-092025-102025-122026-032026-052026-072026-09 2026-04-02 · RedCo II Master Fund, L.P. sold $8.6M2026-04-02 · RedCo II Master Fund, L.P. sold $8.3M2026-03-31 · RedCo II Master Fund, L.P. sold $735.9K2026-03-31 · RedCo II Master Fund, L.P. sold $706.5K2026-04-01 · RedCo II Master Fund, L.P. sold $643.2K2026-04-01 · RedCo II Master Fund, L.P. sold $617.6K
INSIDER SELL
INDEXED RETURN, DIVIDEND-ADJUSTED — NOT A PRICE CHART · LARGE TRADES DRAWN FIRST WHEN A NAME FILES HEAVILY
Live price
Daily candles from TradingView, on their licence — no filings are marked on this one
WHY THIS NAME IS ON THE DESK
The complete filing record, in one place.
The record shows a net $19.6M sold by insiders over 180 days, 70 funds added last quarter. Every figure is a federal filing, dated the day it became public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector from the SEC's own SIC classification
UTHRCPIXMRNAREGNLLYALNYELFCITRMDGLDNAVRTXNUVL
Insider transactions
Form 4 purchases and sales (codes P and S) — grants, option exercises and preferred conversions excluded

Over the last 180 days, ADC Therapeutics SA insiders sold a net $19.6M of stock across 18 Form 4 purchases and sales, with 0 insider(s) buying. Source: SEC Form 4 filings, as of 2026-09-04.

INSIDER
FILED
SHARES
VALUE
RedCo II Master Fund, L.P.
—
SELL
2026-04-02
2,634,506.0
$8.6M
RedCo II Master Fund, L.P.
—
SELL
2026-04-02
2,529,491.0
$8.3M
RedCo II Master Fund, L.P.
—
SELL
2026-04-01
162,517.0
$617.6K
RedCo II Master Fund, L.P.
—
SELL
2026-04-01
169,265.0
$643.2K
RedCo II Master Fund, L.P.
—
SELL
2026-03-31
196,229.0
$735.9K
18 TRANSACTIONS ON RECORD

Showing the most recent few. Create a free account to see 13 more transactions on record, the cross-source screener and CSV export. We store only your email address, and there is no password to create.

Institutional holders
13F · holdings as of the latest quarter funds have reported
Nantahala Capital Management, LLC
24,652,368.0 sh
$26.4M
Redmile Group, LLC
11,526,710.0 sh
$12.3M
TCG Crossover Management, LLC
11,390,175.0 sh
$12.2M
Prosight Management, LP
7,824,749.0 sh
$8.4M
BlackRock, Inc.
7,020,093.0 sh
$7.5M
SCHEDULE 13D/G
No 5%+ ownership filings
Nobody has crossed 5% with a filing obligation. Absence is a fact here, not missing data.
FORM 144
No planned-sale notices
No insider has notified an intent to sell. This is the panel to watch after a run-up.
Fund concentration
N-PORT · funds ranked by how much of THEMSELVES they put in this stock — the conviction number 13F cannot show
Eventide Healthcare & Life Sciences Fund
$21.4M POSITION · AS OF 2026-03-31
1.3%
VANGUARD U.S. MOMENTUM FACTOR ETF
$1.3M POSITION · AS OF 2026-02-28
0.1%
SMALL COMPANY GROWTH PORTFOLIO
$420.6K POSITION · AS OF 2026-03-31
0.0%
VANGUARD RUSSELL 2000 GROWTH INDEX FUND
$323.9K POSITION · AS OF 2026-02-28
0.0%
Clearwater Select Equity Fund
$60.9K POSITION · AS OF 2026-03-31
0.0%
Small Cap Index Fund
$180.7K POSITION · AS OF 2026-03-31
0.0%
SEC N-PORT, MONTHLY WITH A ~60-DAY PUBLIC LAG · FUNDS ≥ $10M · % = SHARE OF THE FUND'S OWN BOOK
Fundamentals
Annual figures from XBRL filings · pick a past date to see them exactly as the market knew them then — restatements and all
2025-122024-122023-122022-12
REVENUE$81.4M$70.8M$69.6M$74.9M
OPERATING INCOME$-121.5M$-130.7M$-166.0M$-123.3M
NET INCOME$-142.6M$-157.8M$-240.1M$-157.1M
EPS (DILUTED)-1.12-1.62-2.94-2.01
OPERATING CASH FLOW$-141.2M$-123.8M$-118.7M$-138.3M
CASH$261.3M$250.9M$278.6M$326.4M
SEC XBRL · FISCAL-YEAR PERIODS · AS KNOWN ON 2026-09-04 · NOBODY ELSE SHOWS FUNDAMENTALS AS OF A PAST DATE
W WAVEMAN

Public filings, honestly analyzed. Official US government sources in one desk — every figure carries the date it was filed, and the methodology is published, backtest included.

SEC FORM 4FORM 13F 13D/GFORM 144XBRL STOCK ACTCONTRACTSFEC CFPBNRC
PRODUCT
DeskBacktester CompaniesAccount
SUPPORT
FAQMethodology Contact
LEGAL
TermsPrivacy Accessibility
© 2026 WAVEMAN · SOURCE: SEC EDGAR & OFFICIAL GOVERNMENT DATA · NOT INVESTMENT ADVICE · CHART BY TRADINGVIEW · UPDATED 2026-09-04 ALL SYSTEMS LIVE FOR MACHINES →